Immix Biopharma, Inc. (IMMX) Stock

Immix Biopharma, Inc. (IMMX) is a Healthcare stock trading at $8.71 (as of 2026-06-18), with a market capitalization of $489.70M and a trailing P/E of -9.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation in the United States and Australia. Its pipeline includes IMX-110 for soft tissue sarcoma and solid tumors, IMX-111 for colorectal cancer, and IMX-120 for ulcerative colitis and severe Crohn’s disease, including a collaboration with BeiGene for a combination solid-tumor Phase 1b study.

Valuation — source: SEC EDGAR (first-party)
Price	$8.71
Market Cap	$489.70M
P/E Ratio	-9.5
EV / EBITDA	-11.0
Price / Book	5.62
Price / Sales	422.70
DCF Value (model)	$-6.15
DCF Upside vs Price	-170.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$555526.00
Net Margin	-5299.2%
Return on Equity	-41.5%
Current Ratio	8.76
Revenue Growth (YoY)	-45.4%
EPS Growth (YoY)	17.1%
FCF Growth (YoY)	56.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	23.77 (safe)

Valuation vs Sector & Industry
Stock P/E	-9.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-145.4%
vs Industry	-155.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($43.70M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ilya Rachman
Employees	18
Country	US
IPO Date	2021-12-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.